SEC Form 4 · accession 0001209191-17-040831
NovoCure Ltd · NVCR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Asaf Danziger
Officer — Chief Executive Officer · Director
Period of report
Jun 15, 2017
Accepted (ET)
Jun 19, 2017 · 4:31 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001645113
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Jun 15, 2017 | S | 33,245 | $15.187 | D | 1,030,849 | D | |
| Ordinary SharesF2 | Jun 16, 2017 | S | 9,212 | $15.018 | D | 1,021,637 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On June 15, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 33,245 shares in multiple trades at prices ranging from $15.00 to $15.45. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
- F2On June 16, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 9,212 shares in multiple trades at prices ranging from $15.00 to $15.10. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.